Evidence map›Paper›PMID 36412837›Full record

ReviewAntibodies (Basel, Switzerland)2022

Structural Investigation of Therapeutic Antibodies Using Hydroxyl Radical Protein Footprinting Methods.

Corie Y Ralston, Joshua S Sharp

Abstract readReview
In one paragraph

Review in Antibodies (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Corie Y RalstonMolecular Foundry Division, Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Berkeley, CA 94720, USA.ORCID 0000-0002-7899-0951
Joshua S SharpDepartment of BioMolecular Sciences, University of Mississippi, Oxford, MS 38677, USA.ORCID 0000-0002-0115-0276

Funding

Molecular Structure Determination by Mass Spectrometry and Computational ModelingR01GM127267 · NIGMS · UNIVERSITY OF MISSISSIPPI · PI Joshua S Sharp · 2018 to 2026
$3.8M
Development of high-dose time-resolved x-ray footprinting technologies to enable the next level of structural analysis for challenging biological problemsR01GM126218 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI RALSTON, CORIE Y · 2018 to 2025
$3.4M
NIGMS NIH HHS R01 GM126218NIGMS NIH HHS R01 GM127267
6 · The paper itself

Abstract

Commercial monoclonal antibodies are growing and important components of modern therapies against a multitude of human diseases. Well-known high-resolution structural methods such as protein crystallography are often used to characterize antibody structures and to determine paratope and/or epitope binding regions in order to refine antibody design. However, many standard structural techniques require specialized sample preparation that may perturb antibody structure or require high concentrations or other conditions that are far from the conditions conducive to the accurate determination of antigen binding or kinetics. We describe here in this minireview the relatively new method of hydroxyl radical protein footprinting, a solution-state method that can provide structural and kinetic information on antibodies or antibody-antigen interactions useful for therapeutic antibody design. We provide a brief history of hydroxyl radical footprinting, examples of current implementations, and recent advances in throughput and accessibility.

Indexed as

fast photochemical oxidation of proteins (FPOP)flash oxidation (FOX)hydroxyl radical footprintingstructural mass spectrometrytherapeutic antibody structureX-ray footprinting with mass spectrometry (XFMS)

Identifiers

PMID36412837
PMCPMC9680451

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.